7 hrs ago
Research and Markets: Adult and Adolescent Vaccines Market to 2018 -...
Pharmaceutical giants GlaxoSmithKline and Merck are fighting it out in the vaccination market, as countries pick sides in their cervical cancer vaccination programs.
Trending on the Topix Network
12 hrs ago
Michael Sobell Hospice to hold spring sale
Michael Sobell Hospice, at Mount Vernon Hospital, will be hosting the event, which will take place on Wednesday, March 26 between 11am and 3pm.
Thu Mar 06, 2014
Avoid the Anti-Corruption "Blacklist:" Chinese Agency Guidance
Circular No. 50, together with Circular No. 49 which a NHFPC sub-agency issued in December 2013 to regulate the compliance conduct of hospitals in China, follow closely on the heels of the Chinese government's recent investigation into GlaxoSmithKline s sales and marketing practices.
Dartford's former GlaxoSmithKline set to get road names relating to...
An American explorer who reached the North Pole in 1909, another who died in the Antarctic and a Polar explorer are all set to have roads named after them in Dartford.
Wed Mar 05, 2014
Marcus Evans, Life Science and Pharma Conferences Release: Utilizing...
With constantly evolving FDA regulations, it is becoming difficult for pharmaceutic al companies to create and maintain complian t labels.
GlaxoSmithKline Is A Must-Pick For Dividend Investors
The healthcare sector has some of the best dividend payers in the marker. These companies generate massive revenues and cash flows, which allows them to grow the dividends at an impressive rate.
The Jersey Journal
Glaxo, J&J to begin study of long-acting drug to combat AIDS
GlaxoSmithKline and Johnson & Johhnson will begin to test the first monthly injections of experimental AIDS drugs in a study that may transform the treatment of the deadly disease.
GSK - The Quiet Turnaround
Over the past few years, GSK has been quietly executing on an impressive pipeline, with 15 new medications and vaccines launched in the past 5 years - 6 within the past year.
Tue Mar 04, 2014
Wall St. Cheat Sheet
Can GlaxoSmithKline Move Higher?
GlaxoSmithKline is global healthcare group engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products.
Glaxo's U.S. work force shrinking
European drug giant GlaxoSmithKline employed fewer people in the United States in 2013 than at any point since at least 2009, according to its most recent annual report.
Mon Mar 03, 2014
Theravance aims for Q2 split into drug development, royalty companies
Rick Winningham is CEO of Theravance Inc. but won't be allowed to oversee both the company and its drug-development spinoff for more than nine months.
Wall St. Cheat Sheet
GlaxoSmithKline Hits Pause on Early Stage Experimental Inflammatory Drug
GlaxoSmithKline's partnership with Galapagos NV has come to a screeching halt after an experimental drug, GSK2586184, which is a proposed treatment for lupus, didn't deliver in Phase II trials.
Applied Clinical Trials
ISIS Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.
Sun Mar 02, 2014
Wall St. Cheat Sheet
Glaxo's China Probe Means a Bonus Cut for the CEO
GlaxoSmithKline's executives saw smaller bonuses this year than "they might otherwise have been," due primarily to the aftermath of a massive corruption scandal in China.
Sat Mar 01, 2014
The Motley Fool
Is 2014 Going to Be GlaxoSmithKline's Year?
As a whole host of its Pharmaceutical peers struggle to come to terms with patent expiries and generic competition, GlaxoSmithKline that it will be granted, since positive opinions by the CHMP are usually followed by approval.
Geolas: RTP bridge will 'connect the whole project'
In a chat this morning, Geolas says that, while he hasn't himself used the words "signature bridge," that culminates some of his talking points.
Fri Feb 28, 2014
Promacta (Eltrombopag) Submitted to FDA for Treatment of Severe Aplastic Anemia
A supplemental new drug application has been submitted to the FDA for Promacta for the treatment of cytopenias in patients with severe aplastic anemia who have shown an insufficient response to immunosuppressive therapy .
Bob Ingram lays out four Ds that are bringing America down
In the midst of discussing Research Triangle Park and transit in the Triangle at TBJ 's Power Breakfast Thursday, Bob Ingram gave his perspective on the direction America is heading, as well.
Sector movers: Paper stocks push FTSE 100 higher
Mondi led forestry and paper stocks higher after reporting a surge in annual profit, driven by low costs and exposure to higher growth markets.
Customer Interaction Solutions
Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application...
Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline plc announced today the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for Promacta for the treatment of cytopenias in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy .